Clinical Study

The Soluble Plasminogen Activator Receptor as a Biomarker on Monitoring the Therapy Progress of Pulmonary TB-AFB(+) Patients

Table 2

Comparison between medical records used to monitor TB theraphy progress in Indonesia, that is, patients complaints, BMI (kg/m2), width of lesion, sputum AFB, erythrocyte sedimentation rate (mm/hour), monocyte count (cell/mm2), and soluble urokinase plasminogen activator receptor during the 6-month therapy.

During anti-TB-drugs treatment
No.Medical records and level of suPARBefore Treatment2 months4 months6 monthsP-value <.05

1Patients’ Complaints
 Chronic cough >3 weeks20 (100%)17 (85%)5 (25%)
 Decrease of appetite15 (75%)0 (0%)0 (0%)
 Low grade fever10 (50%)0 (0%)0 (0%)
 Shortness of breath9 (45%)5 (25%)3 (15%)
Hemoptoe9 (45%)0 (0 %)0(0 %)
Chest pain2 (10 %)1 (5 %)1 (5 %)

2BMI18.28 ± 2.1219.18 ± 2.3120.36 ± 2.35.0001

3Width of lesion classificationThoracic Imaging n=20Thoracic Imaging n=20
 Minimal Lesion
 Mod Advance Lesion
 Far Advance Lesion
1 (5%)
7 (35%)
12 (60%)
{Worsen:  0  (0%)  Unchange:  3  (15%)Getting  better:  17  (85%)  }{Worsen:  1  (5%)Unchange:  0  (0%)  Getting  better:  19  (95%)}

4Sputum AFB(+)20 (100%)5 (25%)0(0%)

5ESR84.15 ± 32.4744.10 ± 29.9719.30 ± 13.29.0001

6Monocytes Count847.00 ± 244.52662.00 ± 241.72496.50 ± 129.670.0001

7Level of suPAR12.775 ± 3.9408.019 ± 1.4585.771 ± 0.7965.009 ± 0.842.0001